Cite

HARVARD Citation

    Gross-Goupil, M. et al. (n.d.). 863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. Annals of oncology. p. . [Online]. 
  
Back to record